Wang X, Li Y, Fu J, Zhou K, & Wang T. (2021). ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer. Dove Medical Press.
Chicago Style (17th ed.) CitationWang X, Li Y, Fu J, Zhou K, and Wang T. ARNTL2 Is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer. Dove Medical Press, 2021.
MLA (9th ed.) CitationWang X, et al. ARNTL2 Is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.